ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Conditions
On March6, 2017, Adverum Biotechnologies, Inc. issued a press
release regarding, among other matters, its financial results for
its fourth quarter and year ended December31, 2016. A copy of the
press release is furnished as Exhibit 99.1 to this Form 8-K.
This information in this Item 2.02 of this Form 8-K and the
Exhibit 99.1 attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Press release dated March6, 2017. |
2
About ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM)
Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD). ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Recent Trading Information
ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) closed its last trading session down -0.05 at 2.80 with 133,112 shares trading hands.